Novartis Crosses Below Key Moving Average Level

Share to Facebook Share to Twitter Share to Linkedin In trading on Tuesday, shares of Novartis crossed below their 200 day moving average of $85.10, changing hands as low as $84.78 per share. Novartis...

Novartis CEO says Covid to become endemic, calls for better pandemic preparedness

Novartis said in August that it plans to spin off its generics unit Sandoz to sharpen its focus on its patented prescription medicines. Bloomberg | Bloomberg | Getty Images The chief executive of Swis...

The 12 Best Income Investments for 2023, According to Barron’s

While it might not be a feast now for income-oriented investors, it’s a lot better than the famine that prevailed for much of the past decade. Yields on a range of bond and bond-related investments ro...

The Best Income Investing Ideas for 2023

While it might not be a feast now for income-oriented investors, it’s a lot better than the famine that prevailed for much of the past decade. Yields on a range of bond and bond-related investments ro...

Clovis Enters Bankruptcy With Deal to Sell Cancer-Drug Candidate to Novartis

Clovis Oncology Inc., maker of the ovarian and prostate cancer drug Rubraca, filed for bankruptcy over the weekend with a proposed deal in hand to sell its rights to a cancer therapy under development...

U.S. Companies In China Worried Covid Surge Will Damage Prospects After Upbeat G20 Meeting

American Chamber of Commerce in Shanghai Chairman Sean Stein Sean Stein U.S. companies in China are worried that a surge in Covid cases in the country will hurt consumer and investment spending right ...

3 Productivity Tips For Focusing This Fall

As Summer Fridays and out-of-office messages wind down, it’s essential that we find new ways to stay … [+] focused. Shutterstock America’s employees have reported increased distraction in 2022 w...

Novartis Looks Appealing, Based on Drug Pipeline and Planned Spinoff

Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the vi...

Close The Gap Between Discovery Research And Patient Care: Cancer Moonshot Pathways

“New, transformative technologies will improve and simplify screening and we should prioritize these … [+] advancement efforts” Andrea Myers Note: President Joe Biden in February lau...

Novartis Will Cut 8,000 Jobs Under CEO’s Shake-Up Plan

Text size Vasant Narasimhan, CEO of Novartis. ERIC PIERMONT/AFP/Getty Images Pharmaceutical giant Novartis said Tuesday it will lay off more than 7% of its workforce, just a few months after CEO Vas N...

U.S. Firms In Shanghai Cutting Revenue Forecasts, Investment Plans After Lockdowns — Survey

A police patrol vehicle monitors the crowd along Shanghai’s iconic Bund on June 1. Lockdown … [+] restrictions have eased in much of the city this month but residents face stringent travel...

Big Pharma Has Enough Cash to Buy All of Biotech. Why M&A Isn’t Happening.

Text size Late last year, Barron’s predicted a wave of deals, citing biotech companies’ cash holdings. Above, the plates used to print one-dollar bills. Alex Wong/Getty Images With biotech...